Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Fukuda

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Cancer Reports (Hoboken, N.J.)|December 9, 2020
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patientsNaoki Fukuda, Mayu Yunokawa, Yu Fujiwara, et al.
Anticancer Research|February 27, 2026
Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib TherapyMasanari Tsuji, Kazuo Kobayashi, Kazuyoshi Kawakami, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 22, 2022
Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma - A Single Institute AnalysisXiaofei Wang, Kenji Nakano, Taro Shiga, et al.
Plos One|November 16, 2023
Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinomaYoshikazu Tateai, Kazuyoshi Kawakami, Minori Teramae, et al.
Investigational New Drugs|February 9, 2021
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsNoboru Yamamoto, Toshio Shimizu, Kan Yonemori, et al.
Human Gene Therapy|November 9, 2007
Osteopontin small interfering RNA protects mice from fulminant hepatitisYoshinari Saito, Shigeyuki Kon, Yukio Fujiwara, et al.
Cancer Management and Research|November 19, 2021
Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received ChemoradiotherapyNaomi Hayashi, Yasuyoshi Sato, Yu Fujiwara, et al.
In Vivo (Athens, Greece)|September 3, 2020
Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With LenvatinibNaoki Fukuda, Kazuhisa Toda, Y U Fujiwara, et al.
Anticancer Research|January 9, 2021
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue SarcomaYasuyoshi Sato, Kenji Nakano, Naoki Fukuda, et al.
Endocrine|January 28, 2022
A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patientsNaoki Fukuda, Kazuhisa Toda, Shohei Udagawa, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Cancer Reports (Hoboken, N.J.)|December 9, 2020
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patientsNaoki Fukuda, Mayu Yunokawa, Yu Fujiwara, et al.
Anticancer Research|February 27, 2026
Real-world Analysis of Urinary Protein-to-Creatinine Ratio and Blood Pressure in Lenvatinib TherapyMasanari Tsuji, Kazuo Kobayashi, Kazuyoshi Kawakami, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|March 22, 2022
Assessment of Pazopanib-Related Heart Failure in Patients With Advanced Soft Tissue Sarcoma - A Single Institute AnalysisXiaofei Wang, Kenji Nakano, Taro Shiga, et al.
Plos One|November 16, 2023
Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinomaYoshikazu Tateai, Kazuyoshi Kawakami, Minori Teramae, et al.
Investigational New Drugs|February 9, 2021
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsNoboru Yamamoto, Toshio Shimizu, Kan Yonemori, et al.
Human Gene Therapy|November 9, 2007
Osteopontin small interfering RNA protects mice from fulminant hepatitisYoshinari Saito, Shigeyuki Kon, Yukio Fujiwara, et al.
Cancer Management and Research|November 19, 2021
Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received ChemoradiotherapyNaomi Hayashi, Yasuyoshi Sato, Yu Fujiwara, et al.
In Vivo (Athens, Greece)|September 3, 2020
Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With LenvatinibNaoki Fukuda, Kazuhisa Toda, Y U Fujiwara, et al.
Anticancer Research|January 9, 2021
Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue SarcomaYasuyoshi Sato, Kenji Nakano, Naoki Fukuda, et al.
Endocrine|January 28, 2022
A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patientsNaoki Fukuda, Kazuhisa Toda, Shohei Udagawa, et al.
Pageof 11